Money Talk Sundayz

Money Talk Sundayz

By Stevenson BenoitBusinessInvesting
Download on the App Store

Money Talk Sundayz episodes

  • #Vaxart in the News; Latest Updates; Buy/Sell Signals

    We are literally chasing the coronavirus, the covid-19 virus like a hamster on a wheel. That is not just a saying, that is the truth of the matter when you look at rapidly emerging mutations of the covid-19 virus. While everyone is still focused on the delta strain, the lambda and the mu have already told Covid 1 to hold my beer. And of course, the propaganda machine wants to call it the pandemic of the unvaccinated while vaccinated people continue to catch the virus and in some cases die. But don’t get me wrong, this is not me making a case for or against vaccines. This is me making a case for a viable and feasible tool to help combat it. Ladies and gentlemen, Vaxart.

    Subscribe: https://anchor.fm/moneytalksundayz/subscribe

    Welcome to Money Talkz. If you’re new here, I’m your Investment Bro Stevie Bee. Leave a like, share, and or subscribe on your way in the door. If you’re feeling the episode and would like to see more, you can support the channel by clicking the link below. Let’s get into VXRT.

    Vaxart Inc. (VXRT) is trending lower, roughly -4.57% in the recent trading with $8.19 being its most recent. The current price level is over -66.43% lower than the highest price of $24.90 over the past 52-weeks, but it is also 138.86% higher than the lowest price of $3.50 the company dropped to in the past 52-weeks. The latest news story on VXRT appeared in PR Newswire under the title “Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference”.

    The conference was held over the last two days, and I’ll sum up what I’ve watched so far but before that, let’s talk charting.

    VXRT in the last 30 days is trading almost 15% below its one month high and about 10% above its recorded lowest over the same time span. If you check the simple moving averages of VXRT, its 50-day-SMA is $8.27. It’s 5-day-SMA is 8.70. Vaxart’s 200-day-SMA is 7.55.

    The stock’s 20-day average volume is at 4,041,925 shares and 50% of short-term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 7,578,720 shares. And to end, VXRT’s 100-day average volume is 15,462,688 shares with 100% of the long-term indicators pointing towards Buy for the stock.

    In the bigger picture you can see it is trending higher overall.

    Now it’s hard to say how well the stock will do in the long run. Investors like myself anxiously await the coveted pill that moves the needle as they say. I’m sure that the institutions holding VXRT shares are anxiously awaiting this pill as well since they own nearly 41%of the stock. The public owns 120.93 million shares and counting.

    The latest SEC filings reveal that stock came across 7 new insider purchases involving 207,119 shares. On the other hand, VXRT has declared 272,958 shares sold in 9 insider transactions over the past three months.

    How does Money Talkz feel about the stock? Just as bullish as ever. It’s a strong buy.

    If you watched their presentation, you will see that their oral Covid vaccine candidate is backed by clinical data that the FDA found encouraging and promising enough to approve Vaxart to move on to Phase 2 clinical trials. That will being later this year. Considering that we’re already in mid-September and it hasn’t kicked off yet to our knowledge, I don’t expect the pill to be released by the end of the year. Maybe mid 2022 if we’re lucky.

    While Covid is the hotly anticipated offering from VXRT however, the pipeline is focused on several oral tablets beyond the covid pill including norovirus, HPV, influenza & RSV.

    But demand is super high for a Covid combatant and thus the focus is on their pill candidate. The pill promises a convenient mode of administration that is rapid and painless. No appointments, lines, or social distancing required.

    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    10 min
  • #Vaxart in the News; Latest Updates; Buy/Sell Signals

    We are literally chasing the coronavirus, the covid-19 virus like a hamster on a wheel. That is not just a saying, that is the truth of the matter when you look at rapidly emerging mutations of the covid-19 virus. While everyone is still focused on the delta strain, the lambda and the mu have already told Covid 1 to hold my beer. And of course, the propaganda machine wants to call it the pandemic of the unvaccinated while vaccinated people continue to catch the virus and in some cases die. But don’t get me wrong, this is not me making a case for or against vaccines. This is me making a case for a viable and feasible tool to help combat it. Ladies and gentlemen, Vaxart.

    Subscribe: https://anchor.fm/moneytalksundayz/subscribe

    Welcome to Money Talkz. If you’re new here, I’m your Investment Bro Stevie Bee. Leave a like, share, and or subscribe on your way in the door. If you’re feeling the episode and would like to see more, you can support the channel by clicking the link below. Let’s get into VXRT.

    Vaxart Inc. (VXRT) is trending lower, roughly -4.57% in the recent trading with $8.19 being its most recent. The current price level is over -66.43% lower than the highest price of $24.90 over the past 52-weeks, but it is also 138.86% higher than the lowest price of $3.50 the company dropped to in the past 52-weeks. The latest news story on VXRT appeared in PR Newswire under the title “Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference”.

    The conference was held over the last two days, and I’ll sum up what I’ve watched so far but before that, let’s talk charting.

    VXRT in the last 30 days is trading almost 15% below its one month high and about 10% above its recorded lowest over the same time span. If you check the simple moving averages of VXRT, its 50-day-SMA is $8.27. It’s 5-day-SMA is 8.70. Vaxart’s 200-day-SMA is 7.55.

    The stock’s 20-day average volume is at 4,041,925 shares and 50% of short-term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 7,578,720 shares. And to end, VXRT’s 100-day average volume is 15,462,688 shares with 100% of the long-term indicators pointing towards Buy for the stock.

    In the bigger picture you can see it is trending higher overall.

    Now it’s hard to say how well the stock will do in the long run. Investors like myself anxiously await the coveted pill that moves the needle as they say. I’m sure that the institutions holding VXRT shares are anxiously awaiting this pill as well since they own nearly 41%of the stock. The public owns 120.93 million shares and counting.

    The latest SEC filings reveal that stock came across 7 new insider purchases involving 207,119 shares. On the other hand, VXRT has declared 272,958 shares sold in 9 insider transactions over the past three months.

    How does Money Talkz feel about the stock? Just as bullish as ever. It’s a strong buy.

    If you watched their presentation, you will see that their oral Covid vaccine candidate is backed by clinical data that the FDA found encouraging and promising enough to approve Vaxart to move on to Phase 2 clinical trials. That will being later this year. Considering that we’re already in mid-September and it hasn’t kicked off yet to our knowledge, I don’t expect the pill to be released by the end of the year. Maybe mid 2022 if we’re lucky.

    While Covid is the hotly anticipated offering from VXRT however, the pipeline is focused on several oral tablets beyond the covid pill including norovirus, HPV, influenza & RSV.

    But demand is super high for a Covid combatant and thus the focus is on their pill candidate. The pill promises a convenient mode of administration that is rapid and painless. No appointments, lines, or social distancing required.

    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    10 min
  • Ethereum Killer Solano; Next SOL Token on the Way!

    It’s that time of the season again. The witching hour is among us. Open contracts come to a close and either money is made or lost but the reset button has been pressed. All eyes will be on the mother of all squeezes in AMC and other so-called meme stocks like GME and other retail investor favorites. In crypto news, the market as a whole is in a bit of a slump over the past few days. One coin that remains resilient through the choppiness is again Solana, but this coin is looking to be SOL 2.0. Are you ready?  

    Subscribe: https://anchor.fm/moneytalksundayz/subscribe 

    Welcome to another episode of Money Talk Sundayz. I’m your Investment bro, Stevie Bee. You know the drill, hit that like share and subscribe and let’s jump right into it.

    Crypto is ablaze and last week’s coin of the week is still holding ground. As other major coins tear Solana is ripping at a fraction. The Ethereum challenger has been seeing more interest from institutional players according to Sam Bankman-Fried, CEO of FTX exchange.

    Solana is an enterprise-grade blockchain, which was created by Anatoly Yakovenko. It is backed by Alameda Research and FTX Exchange, which all fall under the watchful eye of crypto billionaire Sam Bankman-Fried. According to Bankman-Fried, Solana’s compelling long-term roadmap as a blockchain means that it will be able to support industrial uses of crypto. According to Bankman-Fried, NFTs, decentralized finance, and the launch of the Pyth Network market-data feed has contributed, at least in part, to Solana’s popularity. Bankman-Fried is busy with the development of the Serum derivatives exchange on top of Solana’s network.

    Solana’s SOL token has seen its value soar in recent weeks, surpassing Dogecoin, as of September 7, 2021. It now sits sixth, at the time of this writing, at $182.56, surpassing XRP, which has not performed well this week, due in part to legal troubles.

    As good as Solana is doing, this coin seems poised to usurp the Ethereum killer. Pseudonymous trader Inmortal tells his 66,600 Twitter followers that he’s looking at Cosmos (ATOM), a project that aims to help developers build different blockchains that can transact and exchange data, creating a decentralized internet of blockchains. According to the crypto analyst, Atom will be the next Solana (SOL), a crypto asset that has meteorically risen nearly 350% in the last 30 days, according to CoinGecko.

    The crypto analyst is also looking at Cosmos in its Bitcoin pair ATOM/BTC). According to Inmortal, ATOM/BTC must flip 0.00055 ($25) resistance into support to ignite a parabolic rise in value.

    ATOM is doing great and if it follows current projections the pair could rise to as high as 0.002 BTC ($91.14), which represents a potential upside of over 230% from its current price.

    The ATOM coin indicates the formation of a rounded Bottom pattern in the daily timeframe. The key resistance level(neckline) for this pattern is situated at the $30 mark, which the price has currently broken. If the coin manages to provide a proper breakout from this neckline, the ATOM traders can grab an excellent long opportunity in this coin.

    According to the EMA’s, the ATOM coin has a strong bullish trend with its price trading higher than the 20, 50, 100 and 200 EMA. Moreover, the 20 EMA provided strong dynamic support to the coin’s price.

    The RSI value (BULLISH) is at 68, indicating a strong bullish trend in this coin. However, the RSI line shows substantial bearish divergence concerning the coin’s price, suggesting weakness in the bullish momentum.

    After reviewing this coin I’ve opened up a position and started investing. I will continue to invest when it dips and watch it hit triple digits.

    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    10 min
  • Ethereum Killer Solano; Next SOL Token on the Way!

    It’s that time of the season again. The witching hour is among us. Open contracts come to a close and either money is made or lost but the reset button has been pressed. All eyes will be on the mother of all squeezes in AMC and other so-called meme stocks like GME and other retail investor favorites. In crypto news, the market as a whole is in a bit of a slump over the past few days. One coin that remains resilient through the choppiness is again Solana, but this coin is looking to be SOL 2.0. Are you ready?  

    Subscribe: https://anchor.fm/moneytalksundayz/subscribe 

    Welcome to another episode of Money Talk Sundayz. I’m your Investment bro, Stevie Bee. You know the drill, hit that like share and subscribe and let’s jump right into it.

    Crypto is ablaze and last week’s coin of the week is still holding ground. As other major coins tear Solana is ripping at a fraction. The Ethereum challenger has been seeing more interest from institutional players according to Sam Bankman-Fried, CEO of FTX exchange.

    Solana is an enterprise-grade blockchain, which was created by Anatoly Yakovenko. It is backed by Alameda Research and FTX Exchange, which all fall under the watchful eye of crypto billionaire Sam Bankman-Fried. According to Bankman-Fried, Solana’s compelling long-term roadmap as a blockchain means that it will be able to support industrial uses of crypto. According to Bankman-Fried, NFTs, decentralized finance, and the launch of the Pyth Network market-data feed has contributed, at least in part, to Solana’s popularity. Bankman-Fried is busy with the development of the Serum derivatives exchange on top of Solana’s network.

    Solana’s SOL token has seen its value soar in recent weeks, surpassing Dogecoin, as of September 7, 2021. It now sits sixth, at the time of this writing, at $182.56, surpassing XRP, which has not performed well this week, due in part to legal troubles.

    As good as Solana is doing, this coin seems poised to usurp the Ethereum killer. Pseudonymous trader Inmortal tells his 66,600 Twitter followers that he’s looking at Cosmos (ATOM), a project that aims to help developers build different blockchains that can transact and exchange data, creating a decentralized internet of blockchains. According to the crypto analyst, Atom will be the next Solana (SOL), a crypto asset that has meteorically risen nearly 350% in the last 30 days, according to CoinGecko.

    The crypto analyst is also looking at Cosmos in its Bitcoin pair ATOM/BTC). According to Inmortal, ATOM/BTC must flip 0.00055 ($25) resistance into support to ignite a parabolic rise in value.

    ATOM is doing great and if it follows current projections the pair could rise to as high as 0.002 BTC ($91.14), which represents a potential upside of over 230% from its current price.

    The ATOM coin indicates the formation of a rounded Bottom pattern in the daily timeframe. The key resistance level(neckline) for this pattern is situated at the $30 mark, which the price has currently broken. If the coin manages to provide a proper breakout from this neckline, the ATOM traders can grab an excellent long opportunity in this coin.

    According to the EMA’s, the ATOM coin has a strong bullish trend with its price trading higher than the 20, 50, 100 and 200 EMA. Moreover, the 20 EMA provided strong dynamic support to the coin’s price.

    The RSI value (BULLISH) is at 68, indicating a strong bullish trend in this coin. However, the RSI line shows substantial bearish divergence concerning the coin’s price, suggesting weakness in the bullish momentum.

    After reviewing this coin I’ve opened up a position and started investing. I will continue to invest when it dips and watch it hit triple digits.

    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    10 min
  • Mother of All Squeezes Upon Us? AMC, GME, BBIG, NNA, & More

    It’s that time of the season again. The witching hour is among us. Open contracts come to a close and either money is made or lost but the reset button has been pressed. All eyes will be on the mother of all squeezes in AMC and other so-called meme stocks like GME and other retail investor favorites. In crypto news, the market as a whole is in a bit of a slump over the past few days. One coin that remains resilient through the choppiness is again Solana, but this coin is looking to be SOL 2.0. Are you ready?

    Subscribe: https://anchor.fm/moneytalksundayz/subscribe

    Welcome to another episode of Money Talk Sundayz. I’m your Investment bro, Stevie Bee. You know the drill, hit that like share and subscribe and let’s jump right into it.

    Quadwiching is upon us again. Keep an eye on all of your open positions. I currently have a call option open on NNA based on some intel I came across and I’m currently down on it. If by Wednesday I don’t make at least a 30% profit than I’m out. NNA is Navios Maritime, a marine transportation business. It operates in Asia, Europe, and America. The firm owns fleets of crude oil, refined petroleum products, and chemical tankers.

    I also have shares in MMAT, BBIG, BTX, VXRT and more. I anticipate a clearance sale this Friday so I’m saving to go holiday shopping come Black Friday.

    There is one thing though that seems to be on the minds of many stonk traders, what’s going to happen with AMC? Are the institutions going to be able to cover their positions? The government is expected to hit their debt ceiling by mid-October. Naked shorts have flooded the market. Hurricane Ida as created a double whammy of a crisis in the gulf and the northeastern states. Billions of dollars have been poured into the economic recovery plan for this pandemic we’re almost 2 years in on. Threats of a market crash and serious correction are looming. People are nervous and wary as is the market performance over the past week.

    Let’s say things go belly up. Will the institutions pay out to retail traders? Will the government bail out the banks again after over-leveraging? Well like I told another viewer last week, even if the hedgies are called to cover their bets they might not be able to. The amount of ghost shares currently out does need to be paid out but internally, a loophole, a bail out will be proffered. HODLers of AMC will not realize the fruits of their hactivism.

    In a letter to congressional leaders Wednesday, Treasury Secretary Janet Yellen warned of a likely mid-October deadline to raise the debt ceiling. "The most likely outcome is that cash and extraordinary measures will be exhausted during the month of October," she wrote. She said that "waiting until the last minute" to tackle the issue could "cause serious harm to business and consumer confidence."

    The cock fight continues between dems and republicans. Both agree that the debt ceiling needs to be raised but republicans want dems to do it without GOP support. That way, when it blows up they don’t have to take the blame.

    I’m excited to see what happens Friday.

    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    14 min
  • Mother of All Squeezes Upon Us? AMC, GME, BBIG, NNA, & More

    It’s that time of the season again. The witching hour is among us. Open contracts come to a close and either money is made or lost but the reset button has been pressed. All eyes will be on the mother of all squeezes in AMC and other so-called meme stocks like GME and other retail investor favorites. In crypto news, the market as a whole is in a bit of a slump over the past few days. One coin that remains resilient through the choppiness is again Solana, but this coin is looking to be SOL 2.0. Are you ready?

    Subscribe: https://anchor.fm/moneytalksundayz/subscribe

    Welcome to another episode of Money Talk Sundayz. I’m your Investment bro, Stevie Bee. You know the drill, hit that like share and subscribe and let’s jump right into it.

    Quadwiching is upon us again. Keep an eye on all of your open positions. I currently have a call option open on NNA based on some intel I came across and I’m currently down on it. If by Wednesday I don’t make at least a 30% profit than I’m out. NNA is Navios Maritime, a marine transportation business. It operates in Asia, Europe, and America. The firm owns fleets of crude oil, refined petroleum products, and chemical tankers.

    I also have shares in MMAT, BBIG, BTX, VXRT and more. I anticipate a clearance sale this Friday so I’m saving to go holiday shopping come Black Friday.

    There is one thing though that seems to be on the minds of many stonk traders, what’s going to happen with AMC? Are the institutions going to be able to cover their positions? The government is expected to hit their debt ceiling by mid-October. Naked shorts have flooded the market. Hurricane Ida as created a double whammy of a crisis in the gulf and the northeastern states. Billions of dollars have been poured into the economic recovery plan for this pandemic we’re almost 2 years in on. Threats of a market crash and serious correction are looming. People are nervous and wary as is the market performance over the past week.

    Let’s say things go belly up. Will the institutions pay out to retail traders? Will the government bail out the banks again after over-leveraging? Well like I told another viewer last week, even if the hedgies are called to cover their bets they might not be able to. The amount of ghost shares currently out does need to be paid out but internally, a loophole, a bail out will be proffered. HODLers of AMC will not realize the fruits of their hactivism.

    In a letter to congressional leaders Wednesday, Treasury Secretary Janet Yellen warned of a likely mid-October deadline to raise the debt ceiling. "The most likely outcome is that cash and extraordinary measures will be exhausted during the month of October," she wrote. She said that "waiting until the last minute" to tackle the issue could "cause serious harm to business and consumer confidence."

    The cock fight continues between dems and republicans. Both agree that the debt ceiling needs to be raised but republicans want dems to do it without GOP support. That way, when it blows up they don’t have to take the blame.

    I’m excited to see what happens Friday.

    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    14 min
  • Solana (SOL) Crypto Prices Surge; ETH Killer Making Moves

    What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.

    In crypto news the market overall is experiencing an upswing. BTC being the biggest dog on the block all the other crypto are gunning for the top spot. Despite’s btc’s 50K sticker Solana (SOL) outperformed bitcoin. Solana ranked number 7, is a single chain, delegated proof of stake protocol whose focus is on delivering scalability without sacrificing decentralization or security.

    Core to Solana’s scaling solution is a decentralized clock titled Proof-of-History (PoH), built to solve the problem of time in distributed networks where there is not a single, trusted, source of time. By using Verifiable Delay Functions, PoH allows each node to locally generate timestamps with SHA256 computations. This eliminates the need for the broadcasts of timestamps across the network, improving overall network efficiency.

    Big moves from Solana have thrust it into the crypto limelight. Year-to-date gains come in at a whopping +6,100%, with a significant proportion of that coming over the last two weeks.

    The Solana team states the technology employed in PoH enables the network, of 200 nodes, to sustain a throughput of 50,000 transactions a second with GPUs. They also claim the high scalability and quick transaction times have attracted a lot of institutional interest.

    Solana's support for smart contracts enables it to be used for NFTs, decentralized finance and other blockchain-based applications—and has helped make it a popular competitor to Ethereum, even earning it the moniker "ETH killer," alongside tokens like Polkadot and Cardano. The blockchain claims to offer faster transaction speeds than Ethereum, but currently only handles about 6,000 transactions per second—a fraction of the more than 50,000 it claims to support.

    Meanwhile, the price of Solana's native sol token hit an all-time high of $145.22 Friday morning, surging nearly 25%—the best-one day gain among top cryptocurrencies—to help it overcome meme token dogecoin as the world's seventh-largest cryptocurrency.

    In a sign Solana may be gaining legitimacy as a long-term investment, Jonas Luethy, a sales trader at London-based digital asset broker GlobalBlock, said its token's price gains seemed to be driven by direct purchases without debt, as opposed to the speculative leveraged trading that's driven many of the gains in tokens like dogecoin.

    One thing to watch for of course is the ever pressing need for regulation in the wild wild west of digital currency. Last month, Gary Gensler, chair of the Securities and Exchange Commission, identified decentralized finance, which offers cryptocurrency loans that bypass traditional financial intermediaries like banks, as one of the main areas in the industry that may warrant additional regulation. Over the weekend, the value of decentralized finance projects pinned to the Solana's blockchain surpassed $3 billion for the first time ever, nearly tripling this month alone.


    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    13 min
  • Solana (SOL) Crypto Prices Surge; ETH Killer Making Moves

    What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.

    In crypto news the market overall is experiencing an upswing. BTC being the biggest dog on the block all the other crypto are gunning for the top spot. Despite’s btc’s 50K sticker Solana (SOL) outperformed bitcoin. Solana ranked number 7, is a single chain, delegated proof of stake protocol whose focus is on delivering scalability without sacrificing decentralization or security.

    Core to Solana’s scaling solution is a decentralized clock titled Proof-of-History (PoH), built to solve the problem of time in distributed networks where there is not a single, trusted, source of time. By using Verifiable Delay Functions, PoH allows each node to locally generate timestamps with SHA256 computations. This eliminates the need for the broadcasts of timestamps across the network, improving overall network efficiency.

    Big moves from Solana have thrust it into the crypto limelight. Year-to-date gains come in at a whopping +6,100%, with a significant proportion of that coming over the last two weeks.

    The Solana team states the technology employed in PoH enables the network, of 200 nodes, to sustain a throughput of 50,000 transactions a second with GPUs. They also claim the high scalability and quick transaction times have attracted a lot of institutional interest.

    Solana's support for smart contracts enables it to be used for NFTs, decentralized finance and other blockchain-based applications—and has helped make it a popular competitor to Ethereum, even earning it the moniker "ETH killer," alongside tokens like Polkadot and Cardano. The blockchain claims to offer faster transaction speeds than Ethereum, but currently only handles about 6,000 transactions per second—a fraction of the more than 50,000 it claims to support.

    Meanwhile, the price of Solana's native sol token hit an all-time high of $145.22 Friday morning, surging nearly 25%—the best-one day gain among top cryptocurrencies—to help it overcome meme token dogecoin as the world's seventh-largest cryptocurrency.

    In a sign Solana may be gaining legitimacy as a long-term investment, Jonas Luethy, a sales trader at London-based digital asset broker GlobalBlock, said its token's price gains seemed to be driven by direct purchases without debt, as opposed to the speculative leveraged trading that's driven many of the gains in tokens like dogecoin.

    One thing to watch for of course is the ever pressing need for regulation in the wild wild west of digital currency. Last month, Gary Gensler, chair of the Securities and Exchange Commission, identified decentralized finance, which offers cryptocurrency loans that bypass traditional financial intermediaries like banks, as one of the main areas in the industry that may warrant additional regulation. Over the weekend, the value of decentralized finance projects pinned to the Solana's blockchain surpassed $3 billion for the first time ever, nearly tripling this month alone.


    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    13 min
  • BBIG Moon Landing; Vinco Ventures Squeeze on the Way

    What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.

    Vinco Ventures' (BBIG) stock price has remained very volatile in the last few days. On an overall basis, it has gained 160 percent in the last month or so. Since the beginning of 2021, BBIG stock is up by more than 480 percent.

    Vinco Ventures is an acquisition company that focuses on the B.I.G. (buy, innovate, grow) strategy. It mainly works in the media and content space and tries to leverage the internal traffic platforms of Honey Badger and Social Pulse Media to determine the highest conversion traffic and target accordingly.

    There have been many developments that have led to the wild ride for BBIG stock. First, BBIG and its joint venture partner Zash Global Media and Entertainment acquired a short-form video platform in July. Lomotif has more than 225 million app installations and over 31 million monthly active users worldwide. Since CCV's investment in 2018, the company has been among the fastest rising video-sharing social networking platforms, with 225+ million Lomotif app installations in over 200 international locations in 300+ languages. In accordance with outdoors monitoring providers, over 300 million movies are played on the platform monthly. Over 10 billion atomic UGC (User Generated Content) clips have been used to create greater than 750 million movies on the platform since its launch. In August, BBIG also launched a platform for music streaming and NFTs.

    Another major catalyst for BBIG stock has been its rising popularity with social media sites, especially on Reddit and Stocktwits. The users are praying for a short squeeze and are buying the shares and call options with a potential short squeeze in mind.

    The number of shares shorted is relatively small compared to the average trading volume of the stock. Therefore, the short squeeze catalyst might exhaust itself soon.

    Recently, the company reported its second-quarter results, which were disappointing. Its operating loss for the second quarter was $4.97 million compared to $1.2 million in the second quarter of 2020. Its revenues for the second quarter of 2021 also declined by 48 percent YoY. Its financials haven't provided much strength to its fundamental investment case.

    As far as valuation is concerned, BBIG stock is currently trading at a Last Twelve Months  Enterprise Value-to-revenue multiple of 34.8x. According to Yahoo Finance, the industry average is 1.65x. Therefore, BBIG is trading at a much higher premium than the industry. A lot of optimism has already been priced into the stock with nearly 500 percent gains YTD.

    The stock closed Friday at 7.98 well above its 20-day moving average of 4.24. it had a trading volume of 126.6 million shares indicating a high interest and lots of activity/volatility in this stock. The shares traded lower with abnormally high volume most likely attributed to retail investors raking in profits. According to data from Benzinga Pro, Vinco Ventures has a total share float of 60.01 million, of which 11.67 million shares are sold short, representing 19.44% of shares sold short.


    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    13 min
  • Vaxart vs Oramed (VXRT v ORMP) Money Talk Sundayz

    What up Bros Nation! How is it going?! I don’t know about you but this past week has felt kind of long with no midweek Money Talkz check in. How has the market been treating you? In my case I had my shares of ups and downs but for the week I’m up several hundred dollars across various investments. On the crypto side of things I’d say about the same. I’m up over seven hundred dollars through various crypto investments. Slow and steady progress while waiting for that one breakout. Anyway, welcome to another episode of Money Talk Sundayz. It’s your big bro Stevie Bee. Hit that like share and subscribe button on your way in the door. Let’s get to the news.

    Call it the stock market’s version of the “sequel effect.” January’s meme stock runup was so enjoyable that investors can’t help but try short squeezes again. This week, the 15 most shorted stocks have risen 31%, wildly outperforming the S&P 500’s 0.76% gain over the same time. SPACs are just collateral damage of attention-deficit investors.

    Vaxart, vaxart, vaxart. While doing my review of Vaxart for today’s episode I came across another biotech stock that’s competing with VXRT. That company is Oramed Pharmaceuticals. Oramed is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM.

    Knowing there is another company working on a Covid pill how do they compare? Let’s start with the house favorite, VXRT.

    Off rip, Vaxart has already obtained the FDA approval to begin phase 2 clinical trials with its tablet vaccine candidate. That trial will be commencing shortly. As of this recording VXRT is trading at 8.71. It closed Friday September 3rd 11 cents below it’s 20 day moving average with a trading volume of 2.89 million. The firm has a fifty day simple moving average of $8.17 and a 200-day simple moving average of $7.30. The company has a market capitalization of $1.10 billion.

    Notably, Julie M. Cherrington joined VXRT Board of Directors. When Julie joined the board of Rakovina Therapeutics this is what they had to say about her.

    "Julie M. Cherrington is an accomplished life science executive with a record of demonstrated success bringing drug candidates into human clinical trials and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products…”

    She is a driving force for multiple products getting FDA approved and moved to market. She’s also served on the board of Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics to name a few.

    Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.

    Her credentials are not to be effed with at all. With that being said, Vaxart is in a good place to make some real game changing moves.

    Oramed on the other hand has a few factors tipping the scale in their favor. Oramed (ORMP) has outperformed even Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX), the established vaccine makers that have already received FDA authorization for their messenger-RNA-based shots.

    ---
    This episode is sponsored by
    · Anchor: The easiest way to make a podcast. https://anchor.fm/app
    ---
    Send in a voice message: https://anchor.fm/moneytalksundayz/message
    16 min

About Money Talk Sundayz

From the publisher's feed

Become a Paid Subscriber: https://anchor.fm/moneytalksundayz/subscribe